<DOC>
	<DOCNO>NCT00128063</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetic behavior Suc-HSA consecutive daily intravenous ( i.v . ) dose . The secondary objective evaluate safety tolerability antiretroviral immunological effect consecutive daily i.v . dose Suc-HSA .</brief_summary>
	<brief_title>Succinylated Human Serum Albumin ( Suc-HSA ) HIV-1 Infection</brief_title>
	<detailed_description>This single centre , single arm study . Subjects receive 5 consecutive daily dose Suc-HSA dose 10 mg/kg day 0 , 1 , 2 , 3 4 Special Investigation Unit ( SIU ) , safety follow SIU 4 hour day 1 2 hour next day . There follow-up visit week 1 , 2 , 4 12 . Standard safety parameter ( physical examination , clinical symptom , laboratory hematology biochemistry ) follow week 12 . Plasma HIV-1 RNA CD4+/CD8+ cell count assess every visit . Plasma drug level ( trough peak ) measure baseline week 2 . 6 patient include study describe protocol amendment . Eligible subject chronic HIV-1 infect patient never treat antiretroviral treatment need start antiretroviral treatment . Test Product : Suc-HSA , candidate HIV-1 fusion inhibitor . Duration treatment : 5 day Criteria evaluation : - Safety : symptom , sign physical examination , standard hematology chemistry laboratory parameters- Efficacy : change plasma HIV-1 RNA CD4+ T cell count - Pharmacokinetics : plasma level Suc-HSA : Cmin , Cmax AUC</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Patient ≥ 18 year age ; 2 . Voluntarily sign informed consent ; 3 . Patient proven HIV1 infection ( positive antibody HIV1 detectable plasma HIV1 RNA ) ; 4 . Patient HIV1 treatment naïve ; 5 . CD4+ Tcell count ≥ 350 x 10^6/L ; 6 . Plasma HIV1 RNA level screen visit least 5.000 copies/ml , vary ± 0.5 log10 copy precede 6 month period ; 7 . Patient participant part 1 original SucHSA study ( protocol . 2003002 , version 2.4 , date 18 November 2003 ) administration SucHSA occur 8 week ago , OR patient participant study ; 8 . Patient one following : heterosexually active , OR heterosexually active female , agree use effective method contraception partner ( combined oral contraceptive pill ; injectable contraceptive ; intrauterine contraceptive device ( IUCD ) ; consistent use condom use ; physiological anatomical sterility partner ) 14 day prior first administration study medication 4 month last , willing undergo urine pregnancy test prior first last administration , OR heterosexually active male , agree use effective method contraception partner day first administration 4 month last administration . 1 . History AIDS define event ; 2 . Use antiretroviral immunomodulatory therapy ; 3 . Any reason start antiretroviral therapy time enrolment expect occur course study time enrolment ; 4 . Presence active , replicate hepatitis B and/or C virus coinfection ; 5 . ASAT and/or ALAT &gt; 3 time upper limit normal ( ULN ) ( AIDS Clinical Trials Group [ ACTG ] toxicity scale ) ; 6 . Serum creatinine measure &gt; 1.5 x ULN ; 7 . Total bilirubin &gt; 2x ULN ; 8 . Neutropenia ( absolute neutrophil count &lt; 1000/mm3 ) ; 9 . Presence clinically significant disease finding screen , opinion investigator could compromise safety subject ; 10 . Patient female ( willing become ) pregnant breastfeeding ; 11 . Any condition , opinion investigator , may interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>succinylated human serum albumin</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>